Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI Topical Gel, 10.3%

About this update from Pelthos Therapeutics Inc.

DURHAM - Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ('Pelthos'), announced it has signed its first commercial agreement to expand patient access for ZELSUVMI (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older ('ZELSUVMI'). Pelthos has entered into an agreement with a Group Purchasing Organization that collaborates with manufacturers on behalf of one of the largest Pharmacy Benefit Managers ('PBMs') in the United States . The PBM manages prescription drug benefits for more than 20 million covered lives, and the formulary inclusion updates for ZELSUVMI started on December 1, 2025 . 'Partnering with a national pharmacy benefit manager is another important milestone in our efforts to achieve increased commercial coverage for ZELSUVMI,' said Scott Plesha , CEO of Pelthos. 'This new partnership will allow an important treatment option to be included in more coverage and distribution networks, thereby improving access for patients and caregivers who are seeking an at-home treatment for molluscum contagiosum.' Pelthos launched ZELSUVMI for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older in July 2025 . ZELSUVMI is a novel, topical nitric oxide-releasing gel for the treatment of molluscum. The once-daily prescription medication is effective, well-tolerated, and convenient for at-home or on-the-go application and can be used to treat molluscum contagiosum infections on the body, including sensitive areas such as the face, groin, or underarms. ZELSUVMI received a Novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum infections. 'This PBM partnership supports our overall patient services plan for ZELSUVMI. We are committed to reducing barriers for patients and providing access to our novel medication ZELSUVMI for those patients suffering from molluscum,' said Sai Rangarao , Chief Commercial Officer at Pelthos. About Molluscum Contagiosum Molluscum is a poxvirus and one of the most common skin infections seen by dermatologists, pediatric dermatologists, and pediatricians. This highly contagious viral skin condition afflicts an estimated 16.7 million people, with up to 6 million new incidents reported every year in the United States , most of them in children. Individuals with compromised immune systems are at an elevated risk of contracting molluscum, with the condition impacting approximately 20% of HIV patients. Molluscum infections spread to others through contact with infected persons or contaminated objects like towels, toys, furniture, swimming pools, and other surfaces. Molluscum infections present with raised, flesh-colored or red bumps that can appear anywhere on the body, including the face, hands, trunk, genitals, back of the knees, armpits, and other sensitive areas. People with molluscum may suffer discomfort from itching, secondary bacterial infections from scratching, or atopic dermatitis, as well as immense social stigma from having visible molluscum lesions that may persist for months to years. It is estimated that 30% of children will have lesions that persist beyond 18 months.5 Up to 73% of children with molluscum go untreated. About ZELSUVMI (berdazimer) topical gel, 10.3% ZELSUVMI (berdazimer) topical gel, 10.3% is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. ZELSUVMI received a novel drug designation from the U.S. Food and Drug Administration in 2024 and is the first and only approved topical prescription medication that can be applied by patients, parents, or caregivers at home, outside of a physician's office, or other medical setting to treat this highly contagious viral skin infection. The product was developed using the proprietary nitric oxide-based technology platform, NITRICIL, now owned by Ligand Pharmaceuticals Incorporated . Complete prescribing information and important safety information is available at www.zelsuvmi.com. Contact: Mike Moyer Email: [email protected] Kellie Walsh Email: [email protected] Tel: (914) 315-6072 (C) 2025 Electronic News Publishing, source ENP Newswire

View stock analysis, news, and events for Pelthos Therapeutics Inc.